Physician profile
Michael Lyster
NPI 1114916350
$83,721.50
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $143 · 2021: $995 · 2022: $919 · 2023: $289 · 2024: $36.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $240 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.35 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $80,577.38 | 2019 | |
| Astellas Pharma US INC | $683.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $215.90 | 2019-2022 | |
| Janssen Biotech, INC. | $204.30 | 2019-2022 | |
| Pfizer INC. | $179.56 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $161.38 | 2022 | |
| Incyte Corporation | $151.28 | 2021-2022 | |
| Exelixis INC. | $137.10 | 2022-2023 | |
| Seagen INC. | $137.03 | 2021-2023 | Adcetris |
| Amgen INC. | $100.49 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $98.68 | 2019-2023 | Lynparza |
| Genzyme Corporation | $94.79 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.32 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $90.89 | 2019-2024 | Opdivo, Krazati |
| Pharmacyclics LLC, An Abbvie Company | $83.81 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.